Cyclomics is a Dutch startup company founded in 2018 by scientists of the UMC Utrecht. Its ambition is to transform cancer care by enabling faster and more reliable diagnoses, particularly in the context of cancer recurrence thanks to its proprietary circulating tumor DNA (ctDNA) detection technology.

Mission – Accurate measurement of cancer recurrence and monitoring of treatment responses are important clinical needs in cancer diagnostics. The limitations of existing (imaging-based) methods poses a significant impediment to effective (re-)treatment and overall survival. The mission of Cyclomics is to address this challenge through an innovative solution for early cancer detection called CyclomicsSeq. This solution consists of a new diagnostic kit that can disrupt the cancer diagnostics market and clinical practice by enabling fast and reliable results, and delivering superior performance to standard radiological and/or physical examination alone. CyclomicsSeq's first application will be for head and neck cancers (HNC), where monitoring of treatment response and recurrence disease is essential for improving survival.

 

Learn more

ABOUT US

140x140

Jeroen de Ridder

  • Co-Founder
  • CEO
  •  

    140x140

    Wigard Kloosterman

  • Co-Founder
  • CSO
  •  

    140x140

    Alessio Marcozzi

  • Co-Founder
  • Principal Scientist
  •  

    140x140

    Myrthe Jager

  • Academic Collaborator
  • Clinical Lead Scientist
  •  

    140x140

    Roy Straver

  • Academic Collaborator
  • Bioinformatics Scientist
  •  

    140x140

    Martin Elferink

  • Academic Collaborator
  • Bioinformatics Scientist
  •  

    TECHNOLOGY

    Cyclomics has developed CyclomicsSeq, a novel ctDNA detection assay based on the latest 3rd-generation (i.e. Nanopore) sequencer which delivers fast, low-cost and point-of-care sequencing. In contrast to available ctDNA-based methods, CyclomicsSeq ensures that even a single ctDNA molecule present in blood can be detected and read (i.e. sequenced) at near 100% accuracy.

     

    Learn more